Literature DB >> 27903335

Patterns of Cortical and Subcortical Amyloid Burden across Stages of Preclinical Alzheimer's Disease.

Emily C Edmonds1, Katherine J Bangen1, Lisa Delano-Wood1, Daniel A Nation2, Ansgar J Furst3, David P Salmon4, Mark W Bondi1.   

Abstract

OBJECTIVES: We examined florbetapir positron emission tomography (PET) amyloid scans across stages of preclinical Alzheimer's disease (AD) in cortical, allocortical, and subcortical regions. Stages were characterized using empirically defined methods.
METHODS: A total of 312 cognitively normal Alzheimer's Disease Neuroimaging Initiative participants completed a neuropsychological assessment and florbetapir PET scan. Participants were classified into stages of preclinical AD using (1) a novel approach based on the number of abnormal biomarkers/cognitive markers each individual possessed, and (2) National Institute on Aging and the Alzheimer's Association (NIA-AA) criteria. Preclinical AD groups were compared to one another and to a mild cognitive impairment (MCI) sample on florbetapir standardized uptake value ratios (SUVRs) in cortical and allocortical/subcortical regions of interest (ROIs).
RESULTS: Amyloid deposition increased across stages of preclinical AD in all cortical ROIs, with SUVRs in the later stages reaching levels seen in MCI. Several subcortical areas showed a pattern of results similar to the cortical regions; however, SUVRs in the hippocampus, pallidum, and thalamus largely did not differ across stages of preclinical AD.
CONCLUSIONS: Substantial amyloid accumulation in cortical areas has already occurred before one meets criteria for a clinical diagnosis. Potential explanations for the unexpected pattern of results in some allocortical/subcortical ROIs include lack of correspondence between (1) cerebrospinal fluid and florbetapir PET measures of amyloid, or between (2) subcortical florbetapir PET SUVRs and underlying neuropathology. Findings support the utility of our novel method for staging preclinical AD. By combining imaging biomarkers with detailed cognitive assessment to better characterize preclinical AD, we can advance our understanding of who is at risk for future progression. (JINS, 2016, 22, 978-990).

Entities:  

Keywords:  Alzheimer disease; Beta-amyloid peptides; Biomarkers; Dementia; Florbetapir; Neuropsychology; Positron emission tomography

Mesh:

Substances:

Year:  2016        PMID: 27903335      PMCID: PMC5240733          DOI: 10.1017/S1355617716000928

Source DB:  PubMed          Journal:  J Int Neuropsychol Soc        ISSN: 1355-6177            Impact factor:   2.892


  58 in total

1.  Susceptibility of the conventional criteria for mild cognitive impairment to false-positive diagnostic errors.

Authors:  Emily C Edmonds; Lisa Delano-Wood; Lindsay R Clark; Amy J Jak; Daniel A Nation; Carrie R McDonald; David J Libon; Rhoda Au; Douglas Galasko; David P Salmon; Mark W Bondi
Journal:  Alzheimers Dement       Date:  2014-05-22       Impact factor: 21.566

2.  Amyloid-β imaging with Pittsburgh compound B and florbetapir: comparing radiotracers and quantification methods.

Authors:  Susan M Landau; Christopher Breault; Abhinay D Joshi; Michael Pontecorvo; Chester A Mathis; William J Jagust; Mark A Mintun
Journal:  J Nucl Med       Date:  2012-11-19       Impact factor: 10.057

3.  Alzheimer's disease: striatal amyloid deposits and neurofibrillary changes.

Authors:  H Braak; E Braak
Journal:  J Neuropathol Exp Neurol       Date:  1990-05       Impact factor: 3.685

4.  Performance characteristics of amyloid PET with florbetapir F 18 in patients with alzheimer's disease and cognitively normal subjects.

Authors:  Abhinay D Joshi; Michael J Pontecorvo; Chrisopher M Clark; Alan P Carpenter; Danna L Jennings; Carl H Sadowsky; Lee P Adler; Karel D Kovnat; John P Seibyl; Anupa Arora; Krishnendu Saha; Jason D Burns; Mark J Lowrey; Mark A Mintun; Daniel M Skovronsky
Journal:  J Nucl Med       Date:  2012-02-13       Impact factor: 10.057

5.  Cerebrospinal fluid biomarker signature in Alzheimer's disease neuroimaging initiative subjects.

Authors:  Leslie M Shaw; Hugo Vanderstichele; Malgorzata Knapik-Czajka; Christopher M Clark; Paul S Aisen; Ronald C Petersen; Kaj Blennow; Holly Soares; Adam Simon; Piotr Lewczuk; Robert Dean; Eric Siemers; William Potter; Virginia M-Y Lee; John Q Trojanowski
Journal:  Ann Neurol       Date:  2009-04       Impact factor: 10.422

Review 6.  The Alzheimer's Disease Centers' Uniform Data Set (UDS): the neuropsychologic test battery.

Authors:  Sandra Weintraub; David Salmon; Nathaniel Mercaldo; Steven Ferris; Neill R Graff-Radford; Helena Chui; Jeffrey Cummings; Charles DeCarli; Norman L Foster; Douglas Galasko; Elaine Peskind; Woodrow Dietrich; Duane L Beekly; Walter A Kukull; John C Morris
Journal:  Alzheimer Dis Assoc Disord       Date:  2009 Apr-Jun       Impact factor: 2.703

7.  Cortical Amyloid Burden Differences Across Empirically-Derived Mild Cognitive Impairment Subtypes and Interaction with APOE ɛ4 Genotype.

Authors:  Katherine J Bangen; Alexandra L Clark; Madeline Werhane; Emily C Edmonds; Daniel A Nation; Nicole Evangelista; David J Libon; Mark W Bondi; Lisa Delano-Wood
Journal:  J Alzheimers Dis       Date:  2016-03-29       Impact factor: 4.472

8.  Detection of Striatal Amyloid Plaques with [18F]flutemetamol: Validation with Postmortem Histopathology.

Authors:  Thomas G Beach; Dietmar Rudolf Thal; Michelle Zanette; Adrian Smith; Christopher Buckley
Journal:  J Alzheimers Dis       Date:  2016-03-31       Impact factor: 4.472

Review 9.  Use of amyloid PET across the spectrum of Alzheimer's disease: clinical utility and associated ethical issues.

Authors:  Antoine Leuzy; Eduardo Rigon Zimmer; Kerstin Heurling; Pedro Rosa-Neto; Serge Gauthier
Journal:  Amyloid       Date:  2014-06-11       Impact factor: 7.141

10.  Clinical and multimodal biomarker correlates of ADNI neuropathological findings.

Authors:  Jon B Toledo; Nigel J Cairns; Xiao Da; Kewei Chen; Deborah Carter; Adam Fleisher; Erin Householder; Napatkamon Ayutyanont; Auttawut Roontiva; Robert J Bauer; Paul Eisen; Leslie M Shaw; Christos Davatzikos; Michael W Weiner; Eric M Reiman; John C Morris; John Q Trojanowski
Journal:  Acta Neuropathol Commun       Date:  2013-10-09       Impact factor: 7.801

View more
  9 in total

1.  Subcortical amyloid load is associated with shape and volume in cognitively normal individuals.

Authors:  Shady Rahayel; Christian Bocti; Pénélope Sévigny Dupont; Maude Joannette; Marie Maxime Lavallée; Jim Nikelski; Howard Chertkow; Sven Joubert
Journal:  Hum Brain Mapp       Date:  2019-05-30       Impact factor: 5.038

2.  Obstructive sleep apnea and longitudinal Alzheimer's disease biomarker changes.

Authors:  Omonigho M Bubu; Elizabeth Pirraglia; Andreia G Andrade; Ram A Sharma; Sandra Gimenez-Badia; Ogie Q Umasabor-Bubu; Megan M Hogan; Amanda M Shim; Fahad Mukhtar; Nidhi Sharma; Alfred K Mbah; Azizi A Seixas; Korey Kam; Ferdinand Zizi; Amy R Borenstein; James A Mortimer; Kevin E Kip; David Morgan; Ivana Rosenzweig; Indu Ayappa; David M Rapoport; Girardin Jean-Louis; Andrew W Varga; Ricardo S Osorio
Journal:  Sleep       Date:  2019-06-11       Impact factor: 5.849

3.  A Three-Factor Structure of Cognitive Functioning Among Unimpaired Carriers and Non-Carriers of Autosomal-Dominant Alzheimer's Disease.

Authors:  Edmarie Guzmán-Vélez; Sehily Jaimes; Daniel C Aguirre-Acevedo; Daniel J Norton; Kathryn V Papp; Rebecca Amariglio; Dorene Rentz; Ana Baena; Eliana Henao; Victoria Tirado; Claudia Muñoz; Margarita Giraldo; Reisa A Sperling; Francisco Lopera; Yakeel T Quiroz
Journal:  J Alzheimers Dis       Date:  2018       Impact factor: 4.472

Review 4.  Imaging biomarkers in neurodegeneration: current and future practices.

Authors:  Peter N E Young; Mar Estarellas; Emma Coomans; Meera Srikrishna; Helen Beaumont; Anne Maass; Ashwin V Venkataraman; Rikki Lissaman; Daniel Jiménez; Matthew J Betts; Eimear McGlinchey; David Berron; Antoinette O'Connor; Nick C Fox; Joana B Pereira; William Jagust; Stephen F Carter; Ross W Paterson; Michael Schöll
Journal:  Alzheimers Res Ther       Date:  2020-04-27       Impact factor: 6.982

Review 5.  The Dichotomy of Alzheimer's Disease Pathology: Amyloid-β and Tau.

Authors:  J Wesson Ashford
Journal:  J Alzheimers Dis       Date:  2019       Impact factor: 4.472

Review 6.  Biomarker-Based Signature of Alzheimer's Disease in Pre-MCI Individuals.

Authors:  Elena Chipi; Nicola Salvadori; Lucia Farotti; Lucilla Parnetti
Journal:  Brain Sci       Date:  2019-08-23

7.  Amyloidosis increase is not attenuated by long-term calorie restriction or related to neuron density in the prefrontal cortex of extremely aged rhesus macaques.

Authors:  G A Stonebarger; H F Urbanski; R L Woltjer; K L Vaughan; D K Ingram; P L Schultz; S M Calderazzo; J A Siedeman; J A Mattison; D L Rosene; S G Kohama
Journal:  Geroscience       Date:  2020-09-02       Impact factor: 7.581

8.  Brain amyloid in virally suppressed HIV-associated neurocognitive disorder.

Authors:  Gemma C Howdle; Yann Quidé; Mustafa S Kassem; Kate Johnson; Caroline D Rae; Bruce J Brew; Lucette A Cysique
Journal:  Neurol Neuroimmunol Neuroinflamm       Date:  2020-05-11

9.  Beam orientation optimization for coherent X-ray scattering from distributed deep targets.

Authors:  Sophya Breedlove; Aldo Badano
Journal:  Biomed Eng Online       Date:  2021-09-15       Impact factor: 2.819

  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.